CureDuchenne Ventures announces an investment in Insmed Incorporated to support the development of INS1201, their next generation gene therapy candidate with a targeted delivery approach designed with the potential to address some of the current limitations of gene therapy. Insmed is also exploring the potential of its RNA end-joining technology to deliver larger dystrophin constructs with a goal of ultimately delivering full-length dystrophin protein.
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
How to Identify and Manage Fat Embolism Syndrome (FES) in Fractures
CureDuchenne Hosts “Champions in Miami” Event on March 9 to Help Find a Cure for Duchenne Muscular Dystrophy
Finding the Right One: Advice from Experts on Dating with a Disability
Make an Impact
You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.Donate